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Abstract Recent studies in various rodent models of
pathologic ventricular hypertrophy report the re-expression
of deiodinase type 3 (D3) in cardiomyocytes. D3 inacti-
vates thyroid hormone (T3) and is mainly expressed in
tissues during development. The stimulation of D3 activity
in ventricular hypertrophy and subsequent heart failure is
associated with severe impairment of cardiac T3 signaling.
Hypoxia-induced signaling appears to drive D3 expression
in the hypertrophic cardiomyocyte, but other signaling
cascades implicated in hypertrophy are also capable of
stimulating transcription of the DIO3 gene. Many cardiac
genes are transcriptionally regulated by T3 and impairment
of T3 signaling will not only reduce energy turnover, but
also lead to changes in gene expression that contribute to
contractile dysfunction in pathologic remodeling. Whether
stimulation of D3 activity and the ensuing local T3-defi-
ciency is an adaptive response of the stressed heart or part
of the pathologic signaling network leading to heart failure,
remains to be established.
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Introduction
Persistent pressure and/or volume overload of the heart
triggers a hypertrophic response that is aimed at normal-
ising the increase in ventricular wall stress and the
accompanying rise in energy turnover. Depending on the
level of hemodynamic load, ventricular remodeling may be
successfully compensatory or it may result in progressive
contractile dysfunction and ultimately heart failure. This
pathologic ventricular hypertrophy is characterized by
changes in cardiomyocyte gene expression that affect
contractile function and energy metabolism. The complex
hypertrophic response is now known to be driven by
numerous interacting signal-transduction pathways that
may be triggered by mechanical stress of the cardiomyo-
cyte as well as by various neurohumoral factors [1–3]. For
the most part, these pathways converge on the promoters of
specific genes changing the expression levels of the enco-
ded proteins.
Under normal conditions, the level of circulating thyroid
hormone (TH) determines the cardiac phenotype to a
considerable extent. This is illustrated by the marked dif-
ferences in cardiac contractility, electrophysiology, and
energy metabolism in the absence of TH (hypothyroidism)
and presence of excess levels (hyperthyroidism) [4]. Some
of these differences are secondary to the effect of the
thyroid status on heart rate and systemic blood pressure,
whereas others result from transcriptional regulation of
genes by TH [4]. Involvement of impaired TH signaling in
pathologic ventricular hypertrophy is suggested by similar
changes in expression of a number of key cardiac genes in
hypothyroidism and in heart failure [4]. Typical examples
are the reduced expression of the sarcoplasmic reticulum
Ca2?-ATPase (SERCA2a) and the myosin heavy chain
(MHC) a isoform, and the increased expression of the
MHCb isoform, although a hypothyroid-like expression
profile does not apply to all genes that are co-regulated by
TH [5]. Reduced TH signaling in the hemodynamically
overloaded heart could in principle result from changes in
the expression of TH receptors or their co-factors; by
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diminished active TH uptake through its transporters; by
the reduction of plasma T3 levels that is seen in severe
illness, including advanced heart failure; or by changes in
cellular metabolism of TH. In this article, we will focus on
the latter possibility and review recent data from different
rodent models showing the induction of a TH-inactivating
enzyme in the chronically overloaded heart. The multiple
mechanisms of induction of this enzyme suggest that
reducing TH signaling in the overloaded heart may be
either an adaptive or ultimately a maladaptive response.
Thyroid-hormone deiodination: activation
and inactivation
The high-affinity ligand of the nuclear thyroid-hormone
receptors is 3,5,30-triiodothyronine (T3), but the thyroid
synthesizes and secretes primarily 3,5,30,50-tetraiodothyro-
nine (T4) under conditions of sufficient iodine intake. T4 is
considered a pro-hormone because of its much lower bio-
logical activity compared to T3. The periferal metabolism of
secreted T4 involves the stepwise removal of iodine residues,
yielding T3 as well as inactive derivatives of the hormone.
These reactions are catalyzed by a group of enzymes called
deiodinases. Three types exist, i.e., D1, D2, and D3. These
oxido-reductases share the presence of the rare amino acid
selenocysteine in the conserved active center of the protein.
However, they differ in their catalytic properties, tissue
distribution and developmental expression (reviewed in [6]).
The principal deiodinative reactions catalyzed by these
enzymes are depicted schematically in Fig. 1.
Removal of an iodine residue from the outer phenolic
ring of T4 yields the active hormone T3. This reaction is
catalyzed by both D1 and D2, with D2 having *1,000-fold
higher affinity for T4 than D1. D1 is primarily expressed in
liver and kidney, whereas D2 is present in a number of
tissues, including brown adipose tissue (BAT), brain,
pituitary, and, at low levels, also in human heart and
skeletal muscle. D1 activity provides the major part of total
plasma T3, but D2 activity in humans also appears to be a
substantial source of extra-thyroidal T3 [7]. Primarily,
however, D2 provides T3 in those tissues where it is
expressed. In brain, D2 activity in tanycytes is also thought
to act in a paracrine fashion, providing T3 for surrounding
neurons [8, 9].
Deiodination of the inner tyrosyl ring of T4 and T3
generates the inactive iodothyronines reverse T3 (3,30,50-
triiodothyronine, rT3) and T2 (3,30-diiodothyronine),
respectively (see Fig. 1). This reaction is also catalyzed by
D1, albeit at low rates. However, sulfation of the phenolic
hydroxyl group of T4 and T3 greatly increases these rates,
while blocking outer-ring deiodination [10]. Iodothyronine
sulfation is at least present in liver and D1 activity is
considered important in the clearance of T4 and T3 [10].
rT3 is also a substrate for D2 to generate T2. The third
deiodinase, D3, has high affinity for both T4 and T3, but it
has exclusively inner-ring deiodinative activity producing
rT3 and T2. This TH-inactivating activity is virtually
absent in adult tissues, with the exception of skin and
different areas and cell types in the brain. It is also high in
placenta and in most fetal tissues, including the heart. The
D3 protein is primarily located in the plasma membrane
and although extracellular catalytic activity of D3 has been
proposed [11], intracellular TH appears to be the principal
substrate for D3 and this is in line with the reducing
environment required for activity [12].
Fig. 1 Principal enzymatic
activities of the deiodinases type
1, 2, and 3. Removal of iodine
(purple spheres) from the outer
ring of T4 (3,5,30,50-
tetraiodothyronine) by D1 and
D2 converts T4 to the active
hormone T3 (3,5,30-
triiodothyronine), with D2
having a higher affinity for T4
than D1. Inner-ring deiodination
of T4 and T3 by D3 generates
the biologically inactive
metabolites reverse T3 (3,30,50-
triiodothyronine) and T2 (3,30-
diiodothyronine), respectively
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It is now becoming clear that the different deiodinase
activities are not static, but that they are highly regulated,
both during development and in adult life [13, 14]. A well-
studied example of this is the induction of D2 activity in
rodent BAT during cold exposure, which results in a local
increase in T3 levels that enables the thermogenic response
of this tissue [15]. Tight regulation of tissue T3 levels is
particularly critical during development. Adult plasma
levels of T3 are not compatible with normal fetal devel-
opment and in mammals high D3 activity in the pregnant
uterus and placenta protects the fetus from too much
maternal TH. In addition, most fetal tissues express D3.
Spatial and temporal patterns of expression of D2 and D3
appear to precisely regulate the T3-dependent aspects of
cell proliferation and, particularly, cell differentiation. For
example, development and maturation of the cochlea in
mice is dependent on induction of D2 activity [16],
whereas repression of D2 activity plays a role during bone
development [17]. Additionally, cell-specific expression of
D3 in the retina during the T3-driven metamorphic climax
in tadpoles orchestrates the development of the adult frog
eye [18]. D3 expression is also essential for the develop-
ment of the thyroid axis in mice [19] and regulated regional
expression of D2 and D3 in the developing human brain is
associated with concomitant up or down regulation of local
T3 levels [20]. Taken together, these data show that reg-
ulated expression of the different deiodinases, either as part
of a developmental program or in response to environ-
mental cues, allows for active modulation of tissue-specific
TH signaling irrespective of systemic hormone levels.
Cardiac deiodinase expression in pathologic
ventricular remodeling
Current studies suggest that activation of TH in the healthy
heart is only marginal. D1 and D2 activity are low in the
rodent myocardium and conversion of T4 accounts for
\7% of cardiac T3 [21, 22]. Equally low levels of deio-
dinase activity have been reported for human cardiac tissue
[23], although D2 mRNA levels are considerably higher
than in rat heart [24]. Overexpression of D2 in mouse
myocardium results in only a mild increase in cardiac T3
levels [25, 26], suggesting that active uptake of T4 by
cardiomyocytes through the recently identified TH trans-
porters [27] may be limited. T3 levels in the healthy heart
are therefore primarily determined by the level of plasma
T3. Nevertheless, the heart does appear to have some
capacity for regulating its T3 levels. Normal cardiac T3
levels were observed in rats subjected to severe iodine
deficiency, which reduces plasma T3 and T4 levels by 50
and 90%, respectively [28]. These low levels of plasma T4
make increased local conversion an unlikely source for the
extra tissue T3, eventhough the cardiac D2 activity
increases under conditions of reduced circulating TH [29].
Alternative options include increased active uptake of T3
or reduced clearance, but these aspects have not yet been
studied.
Myocardial activity of the three deiodinases in cardiac
pathology was determined for the first time in a rat model
of right-ventricular (RV) hypertrophy and failure [22]. In
this model, chronic pulmonary arterial hypertension (PAH)
is induced by a single dose of the pyrrolizidine alkaloid
monocrotaline (MCT). The bioactive metabolite of MCT
selectively injures the vascular endothelium of the lung
vessels and progressive pulmonary vasculitis leads to an
increase in vascular resistance and a gradual rise in arterial
pressure, which in turn induces ventricular hypertrophy.
This hypertrophy progresses to a stable compensated state,
designated HYP, or to congestive heart failure (CHF) and
death within 4–5 weeks, depending on the level of PAH
[22, 30]. A greater degree of RV hypertrophy in the CHF
group compared to the HYP group was associated with
more pronounced changes in gene expression that charac-
terize pathologic remodeling, such as the reduction of
mRNA levels of SERCA2a and the shift in mRNA
expression from the MHCa to the MHCb isoform [22, 30].
The partial shift in MHC isoform expression seen in the
RV of the HYP group was strictly related to hypertrophy of
this ventricle since no change occurred in the left ventricle
(LV). On the other hand, the almost complete shift in the
RV of the CHF group is partly related to hypertrophy and
partly to the reduction of plasma T3 levels in these criti-
cally ill animals, because a significant shift was seen in the
LV. Analysis of deiodinase enzyme activities in the myo-
cardium showed a low level of D1 activity in both
ventricles of control animals, which was reduced in the
HYP and CHF groups [22]. However, the maximal D1
activity was \1% of that found in the livers of these ani-
mals and is consequently thought to be irrelevant for
cardiac TH metabolism [22]. D2 activity could not be
detected in any of the groups, but a low level of D3 activity
was found in LV and RV of control animals. Unexpectedly,
this activity increased in the chronically overloaded RV,
with no change of activity in the LV’s of the same hearts.
The five fold increase in D3 activity in the RV of the CHF
group was furthermore significantly higher than that in the
RV of the HYP group (three fold) [22]. A more extensive
recent analysis of this model showed an average 10-fold
stimulation of RV D3 activity in the CHF group, amount-
ing to *20% of the level of D3 activity found in brains of
these rats [31]. Moderate induction of D3 activity is
therefore associated with the development of compensatory
RV hypertrophy, whereas high levels of D3 activity are
associated with overt RV failure and death in these ani-
mals. In a mouse model of chronic pressure overload of the
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LV due to aortic constriction, Trivieri et al. [26] also
reported a five fold increase in cardiac D3 activity in the
hypertrophic LV, however, absolute activity levels were
not presented in that study.
Induction of D3 activity was also found recently in the
LV following myocardial infarction in rats (MI) [32]. Loss
of viable LV tissue due to MI results in a mixture of
pressure and volume overload, which drives hypertrophic
remodeling of the non-infarcted tissue. A 12-week anal-
ysis of post-MI LV remodeling showed chronic cardiac
dysfunction with reduced ejection fraction and increased
LV end-diastolic diameters. High activity levels of D3
were observed in the infarcted LV at the first week fol-
lowing MI, identical to the levels shown previously for the
overloaded RV in the study by Wassen et al. [22]. The
authors suggest that this activity is responsible for the
transient decrease in plasma T3 levels that is typically
seen during the first 3 weeks following MI [32]. Confir-
mation of this idea awaits analysis of D3 activity at later
time points.
Transient expression of D3 following MI was in fact not
found in a recent study of post-MI LV remodeling in the
mouse [33, 34]. Also in this model, strong induction of D3
was found in the hypertrophic, non-infarcted area of the LV
1 week following MI, but D3 activity remained high at 4
and 8 weeks. Using immunohistochemistry and validated
D3 antibodies, it was also shown for the first time that D3
protein localizes to cardiomyocytes in the hypertrophic LV
[33]. As in the rat model, LV function was severely
reduced from the first week post-MI onward, with
increased LV end-diastolic and end-systolic diameters and
reduced fractional shortening. The D3 activity levels were
again similar to those found in failing RV [22], but
although LV function was compromised in these mice, they
did not succumb to heart failure.
Consequences of cardiac D3 expression in pathologic
ventricular remodeling
The stimulation of TH-degrading activity in hypertrophic
myocardium was suggested to lead to a reduction of T3
levels in cardiomyocytes [22]. Tissue TH content has so
far only been determined in the PAH model of RV failure
[31]. The high D3 activity in the RV in CHF correlated
with a 35% lower total T3 content compared to LV of the
same heart. Furthermore, T3-dependent transcription in
the cardiomyocyte was determined to assess whether T3
signaling was indeed reduced in the hypertrophic RV. An
in vivo T3-transcription probe was used consisting of a
reporter plasmid in which the Firefly luciferase gene is
placed under control of a T3-responsive minimal promotor
that has no cardiac-specific regulatory sequences. Direct
injection of the plasmid, together with a normalisation
plasmid expressing Renilla luciferase, into the free wall of
the RV and LV leads to transfection of only cardiomyo-
cytes. Measurement of tissue luciferase activities after
several days gives a measure of T3-dependent transcrip-
tional activity. Analysis of CHF animals showed that
normalized Firefly luciferase activity remained at control
levels in the LV, but that it was reduced by 45% in the
hypertrophic RV. By comparison, normalized Firefly
luciferase activity showed a 50% reduction in hearts of
animals that were severely hypothyroid (plasma T3:
0.03 nM) compared to euthyroid controls (plasma T3:
0.94 nM). This RV-restricted reduction of T3-dependent
transcriptional activity, together with the results men-
tioned above, suggests that D3 expression in the
remodeling cardiomyocyte reduces cellular T3 content to
a level equal or close to that seen in severe systemic
hypothyroidism. However, at this point it cannot be ruled
out that other changes in the hypertrophic cardiomyocyte
contribute to, or cause the observed reduction of T3-
dependent transcription. Indeed, changes in TR expression
levels, including differential effects on the a1, a2 and b1
isoforms, have been reported in models of LV remodeling
induced by MI [35] and pressure overload [36, 37]. The
role of TRs is still a matter of debate with both increased
and decreased expression of TR being suggested to sup-
press T3 signaling. Nevertheless, in a recent study cardiac
function in a mouse model of LV pressure overload
improved by increasing TR expression through viral
transfection of the myocardium [38].
On the other hand, the view that a reduction of cellular
T3 levels is a principal cause of the hypothyroid condition
of hypertrophic cardiomyocytes is supported by the study
of Trivieri et al. [26]. Cardiac-specific overexpression of
D2 was used in a model of LV hypertrophy and dysfunc-
tion due to aortic constriction. In control mice,
overexpression of D2 increased total cardiac T3 levels by
*25%, resulting in enhancement of contractile function.
When these animals were then subjected to aortic con-
striction, LV hypertrophy developed, but without the
characteristic decrease in SERCA2a and increase in MHCb
expression that is seen in wild-type mice. Preservation of
function in the D2-overexpressing hearts was confirmed in
isolated cardiomyocytes by measurement of Ca2?-tran-
sients and contractility. As mentioned earlier, D3
expression was increased five fold in the hypertrophic LV
in this study, suggesting that the overexpression of D2
maintains T3-responsive gene expression by effectively
balancing the TH-degrading activity of D3. Detailed
analyses of the tissue T3 levels in the hypertrophic LV of
control and transgenic mice are required to show that this is
indeed the case.
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Regulation of cardiac D3 expression in pathologic
ventricular remodeling
A large number of signal-transduction pathways are known
to be involved in ventricular remodeling [1–3]. The out-
come of the process depends on the particular mix of
pathways which results from the type and level of stimu-
lation of the cardiomyocyte, as well as from processes
secondary to remodeling. Surprisingly, stimulation of D3
expression may be accounted for by at least three of these
pathways and the synergistic interactions between them
suggests that expression is potentially regulated over a
wide range. The factors and pathways discussed below are
depicted schematically in Fig. 2.
Hypoxia-inducible factor 1
The DIO3 gene has recently been shown to be a direct
target of hypoxia-inducible factor 1 (HIF-1) [31]. A
reduction of oxygen availability triggers HIF-1 signaling
and its down-stream effects are aimed at reducing cellular
oxygen consumption and stimulating oxygen delivery [39].
HIF-1 is a heterodimer and its activity is determined by the
oxygen-dependent level of the HIF-1a subunit. Under
normoxic conditions HIF-1a is ubiquinated and rapidly
degraded, but as cellular oxygen tension drops, it accu-
mulates and associates with the stably expressed HIF-1b to
form HIF-1. HIF-1 then translocates to the nucleus and
activates a number of genes, many of them involved in
glucose metabolism and angiogenesis. In vitro analysis of
the effect of hypoxia on D3 activity showed strong
induction in human neurons (SK-N-AS cells) and chorio-
carcinoma cells (JEG-3), rhesus monkey hepatocytes
(NCLP6E cells), as well as in rat neonatal cardiomyocytes,
while human endometrial cells and fibroblasts were unre-
sponsive [31]. Induction of D3 activity was dynamic with
transient exposure to hypoxia resulting in a transient
increase in D3 mRNA and protein expression. Further-
more, this induction correlated with increased HIF-1a
levels and ChiP analysis confirmed the direct interaction of
HIF-1 with the DIO3 promoter. The latter most likely
involving a conserved HIF-1-binding site present in this
region. The induction of D3 activity in the hypoxic cells
fits the adaptive response orchestrated by HIF-1, as it
markedly reduces T3-dependent metabolic rate in these
cells [31].
Involvement of HIF-1 signaling in cardiac D3 expres-
sion in vivo is suggested by data from the model of PAH-
induced RV hypertrophy and failure. RV-specific stimula-
tion of D3 mRNA expression and enzyme activity was
associated with a similarly specific stimulation of HIF-1a
levels [31]. This is in line with the earlier reported
increased nuclear HIF-1a content in RV cardiomyocytes
[40] and increased expression of HIF-1 regulated genes
[30]. Similarly, in the mouse model of LV pressure-over-
load in which D3 was induced [26], Sano et al. reported
Fig. 2 Schematic representation of some of the pathways that may
contribute to the expression of D3 in pathologic ventricular remod-
eling. A normal cardiomyocyte is depicted on the left. T3 is taken up
by specific transporters and genes that are transcriptionally regulated
by T3 are characterized by the presence in their promoters of thyroid
hormone response elements (TRE) to which the T3 receptor binds.
HIF-1a is degraded under normoxic conditions, whereas HIF-1b is
stable. Transition to the hypertrophic cardiomyocyte may be triggered
by various stimuli (see text for details). Several signaling pathways
converge on the mitogen activated protein kinases (MAPK), of which
ERK and p38 activate DIO3 gene transcription. Mismatch of oxygen
delivery and consumption, caused by ischemia and/or enlargement of
the cardiomyocyte, results in hypoxia and stabilization of HIF-1a.
Dimerization with HIF-1b forms the HIF-1 complex. HIF-1a may
also be stabilized directly as a result of hemodynamic overload and
mechanical stress. TGFb stimulates the Smad signaling pathway by
phosphorylation of R-Smad2 and -3, which form a complex with
Smad4. Together with HIF-1, phosphorylated ERK, and p38 this
results in the synergistic stimulation of transcription of the DIO3
gene. D3 expression is further stimulated by the secreted morphogen
Sonic hedgehog (Shh) which signals through the Gli family of
transcription factors. D3 activity converts T3 to the inactive
metabolite reverse T3, resulting in reduced T3-dependent gene
expression and a concomitant reduction of contractile activity and
energy turnover
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increased HIF-1 activity to be required for adaptive LV
hypertrophy and angiogenesis [41].
Cardiomyocyte hypoxia can occur in hypertrophy as a
result of a mismatch between oxygen supply and con-
sumption. Capillary density and oxygen diffusion distances
may become limiting factors for the enlarged cardiomyo-
cytes [40], particularly given the higher energy turnover as
a result of the increase in wall tension. HIF signaling
therefore constitutes a secondary pathway affecting gene
expression in hypertrophic remodeling. However, rapid
HIF-1a accumulation was also observed following an
increase in ventricular wall tension under normoxic con-
ditions [42]. The HIF-1 response to this hypertrophy
stimulus appeared to be triggered by stretch-activated
channels signaling through the phosphatidylinositol-3-
kinase pathway. Consequently, HIF-1 may also be a factor
in early hypertrophic signaling irrespective of changes in
oxygen tension.
Hypoxia-triggered HIF-1 signaling may obviously
account for the early induction of D3 expression seen in
cardiac ischemia. HIF-1a levels are increased following
ischemia or MI in rat [43–45], hamster [43], mouse [46],
and human myocardium [47–49]. Studies using transgenics
[46], gene transfer [50] or pharmacological intervention
[51] to increase HIF-1a have clearly shown the adaptive
nature of the HIF-1 response in cardiac ischemia. HIF-1
activation in rodent cardiomyocytes occurred in multiple
areas of the ventricle but the expression persisted particu-
larly in the peri-infarct area. Progressively increasing
expression of HIF-2a was also found in remote areas of the
infarcted rat ventricle for at least 4 weeks following MI
[45]. HIF-2a is structurally related to HIF-1a and similarly
regulated, but its expression has so far been considered to
be mainly involved in the endothelial response to hypoxia.
Persistent HIF-1 signaling in the post-MI ventricle may
also be related to the hypertrophic remodeling of surviving
tissue (see above) and is in line with the observed stable
expression of D3 for up to 8 weeks [33, 34]. Immunohis-
tochemical localization of HIF-1 activation and D3
expression in individual cardiomyocytes is needed to fur-
ther support this suggested route for D3 activation.
Transforming growth factor b
Cellular signaling induced by TGF-b leads to transcrip-
tional activation of the DIO3 gene. This effect was
analysed in detail by Huang et al. using various non-
transformed human cell types [52]. TGF-b-activated cell
surface receptor kinases phosphorylate receptor-associated
members of the Smad family of trans-activating factors (R-
Smad), which then migrate to the nucleus to activate target
genes in conjunction with other transcription factors
(reviewed in [53]). Combinations of the common Smad4
isoform with either the R-Smad2 or -3 isoform strongly
activated the promoter of the DIO3 gene in cell types that
expressed D3 endogenously, such as hepatocarcinoma
cells, fibroblasts and skeletal muscle myocytes [52]. TGF-
b1, -2 and -3 were equally potent and this signaling path-
way is a potential candidate for cardiac D3 regulation,
since TGF-b is known to play a role in the development of
ventricular hypertrophy and adverse remodeling (reviewed
in [54, 55]). TGF-b1 mRNA levels increased rapidly in LV
pressure overload (aortic constriction) in the rat, and either
remained elevated at 28 days [56] or returned to basal
values after 14 days [57]. Similarly, in volume overload
(aortacaval fistula), TGF-b1 mRNA levels increased and
returned to basal levels after 21 days [58]. Following MI in
rat and mouse, TGF-b expression increased throughout the
ventricle, particularly in infarct and border zones, persist-
ing for up to 82 days [59–61].
TGF-b signaling in hypertrophy and heart failure is best
known for its role in activating fibrosis, but more recent
data have shown that it is also involved in cardiomyocyte
hypertrophy. For instance, cardiac hypertrophy induced by
Angiotensin II (Ang II) is in part dependent on the
upregulation of cardiomyocyte TGF-b expression, which
then acts in an autocrine loop to stimulate cell growth
(reviewed in [54]). Ang II stimulation of TGF-b expression
involved the stress-activated branch of the Mitogen Acti-
vated Protein Kinase (MAPK) system, i.e., p38 MAPK.
This factor itself is a down-stream target of TGF-b through
the action of TGF-b-activated kinase 1 (TAK1), which was
shown to be upregulated in cardiomyocytes in non-infarc-
ted myocardium following MI [62]. TAK1 signaling is a
second mode of TGF-b action next to the Smad route.
Involvement of the latter route in TGF-b signaling in
cardiomyocytes is nevertheless also likely, since Smads
were shown to be critical in myocyte proliferation and
growth during development [63]. Additionally, Smads play
a role in hypertrophic remodeling (reviewed in [55]),
including Ang II-induced apoptosis [64].
Involvement of the MAPK system is particularly rele-
vant for a possible mechanism of stimulation of D3
expression. Many stimuli driving hypertrophy converge on
this system, which also includes Extracellular Responsive
Kinase (ERK) MAPK and c-Jun N-terminal kinases (JNKs)
[1–3]. Activation of p38 as well as ERK stimulated D3
expression in a range of human cell types that express D3
[52, 65]. More importantly, D3 induction was greatly
enhanced in these cells when MAPK activation was com-
bined with TGF-b stimulation. Further analysis indicated
synergistic action of Smads and MAPK signaling driving
D3 transcription, possibly involving Sp1 [52]. The rele-
vance of this for the in vivo situation is suggested by the
observation of RV-specific activation of p38 MAPK [30] as
well as increased RV Ang II signaling and TGF-b mRNA
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expression [66] in the rat model of PAH-induced RV
hypertrophy with high D3 expression [31].
Sonic hedgehog
Sonic hedgehog (Shh) is a secreted signaling protein acting
through the Gli-family of transcription factors with
numerous effects in vertebrate development. It determines
patterns of cell proliferation and differentiation, including
cardiomyogenesis and development of the heart [17, 67, 68]
(and references therein). The proliferation-promoting
aspect of Shh/Gli signaling has recently been shown to be
linked to induction of D3 activity [68]. Using malignant
keratinocytes, this study indicated that cell proliferation
depended on the reduction of cellular T3 levels due to D3
activity, which effectively blocks both T3-stimulated dif-
ferentiation and inhibition of progression of the cell cycle.
High D3 activity was also found in vascular tumors in
humans, as well as in a solitary fibrous tumor [69–71]. In
these cases D3 activity reached such high levels that a
systemic hypothyroid condition ensued. Taken together,
these data suggest that D3 is induced as part of the re-
induction of the program of cell proliferation that is
responsible for D3 expression in fetal tissues. This mecha-
nism is not restricted to tumor growth, as a strong induction
of hepatic D3 expression was recently shown in a rat model
of liver regeneration following partial hepatectomy [72].
Several studies indicate that Shh also plays a role in the
adult heart. Shh signaling in cardiomyocytes and perivas-
cular smooth muscle cells is critical for maintaining normal
cardiac function in mice [73] and stimulation of Shh sig-
naling by gene transfer in cardiomyocytes and fibroblasts
preserved LV function in acute and chronic ischemia [74].
Endogenous Shh signaling in the LV was also markedly
upregulated following MI [74]. Thus far, cardiac Shh sig-
naling has not been analyzed for the models of LV or RV
pressure overload in which D3 expression was upregulated.
However, increased proliferation signaling is indicated for
RV hypertrophy, where expression of several factors
involved in cell cycle progression was increased [30],
including cyclin D1, a target of Shh [75].
Cross talk
Results from a number of different research lines suggest
that the signaling pathways discussed above are intercon-
nected. HIF-1a and TGF-b signaling are potentiated by the
strong synergistic action on responsive promoters of HIF-1
and complexes of R-Smad2/3 and Smad 4 (reviewed in
[53]). Furthermore, HIF-1a is stabilized by TGF-b-induced
inhibition of 1a-associated prolyl hydroxylase, the enzyme
responsible for degradation of HIF-1a [76]. Cross talk
between hypoxia- and Shh-signaling has also been
described recently. Normobaric hypoxia in mice was found
to induce Shh signaling in a number of tissues and detailed
analysis using the cardiomyocyte cell line H9C2 showed
direct activation of the Shh pathway by HIF-1a [77]. These
data corroborate the earlier reported HIF-1a-induced re-
entry of the cell cycle in rat cardiomyocytes following MI,
as well as in cultured adult cardiomycytes [44]. HIF-1
signaling, therefore, appears to play a central role in the
induction of D3 expression in adult tissues, as it likely does
during fetal development when tissue-oxygen tension is
low. Irrespective of the pathway stimulating D3 expression,
its fetal characteristic fits the partial re-expression of the
fetal gene profile that characterizes pathologic cardiac
hypertrophy [78].
Concluding remarks and future directions
Reducing T3-dependent energy turnover in the stressed
cardiomyocyte by induction of D3 is consistent with the
adaptive nature of HIF-1 signaling. In contrast to extra-
cellularly activated signaling cascades or increases in wall
stress, HIF-1 signaling would restrict the induction of D3 to
those cells that would benefit from a reduction in energy
turnover. So far, D3-immunohistochemistry has only been
shown in post-MI LV and the mixed pattern of D3-positive
and -negative cardiomyocytes appears to support cell-spe-
cific rather than global induction of D3 expression [33].
When stimulation of D3 activity is compounded by other
factors involved in pathologic remodeling, e.g., TGF-b
signaling, the decrease in cellular T3 levels may further
impact on the expression of T3-dependent genes that are
implicated in the development of contractile dysfunction,
and the adaptive response may become part of the problem.
A maladaptive effect of reduced T3-signaling in heart failure
is still the prevailing view, but the stable induction of D3 in
the post-MI LV [33] and the original study by Wassen et al.
[22], suggest that timing and extent of D3 induction may be
critical factors in turning an adaptive into a maldaptive
response. In the latter study, ventricles that developed stable
compensatory hypertrophy showed significantly less
induction of D3 activity compared to failing ventricles. The
increase in TGF-b signaling in the progression to failure may
play a role here [55]. Given the stimulation of DIO3 gene
transcription by multiple signaling cascades implicated in
hypertrophy, additional studies are needed to deliniate which
factors are driving D3 expression over the course of patho-
logic ventricular remodeling.
Although it is tempting to conclude a causal relationship
between the induction of D3 activity on the one hand, and
adaptive or maladaptive aspects of pathologic hypertrophy
on the other, there are no data as yet to confirm this. There
are no selective inhibitors of D3 activity and a transgenic
Heart Fail Rev (2010) 15:133–142 139
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approach, using cardiac-specific, conditional knock-out of
D3 expression appears to be the optimal way to test the
relevance of D3 activity for the development of adaptive or
maladaptive ventricular remodeling.
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